BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 23470829)

  • 1. [Sustained molecular remission with a tyrosine kinase inhibitor alone for seven months in a patient with Philadelphia chromosome-positive acute lymphoblastic leukemia].
    Takahashi T; Shigeoka T; Suzukawa M; Ishido A; Tominaga T
    Rinsho Ketsueki; 2013 Feb; 54(2):210-3. PubMed ID: 23470829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
    Steinberg M
    Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tyrosine kinase inhibitor use in pediatric Philadelphia chromosome-positive acute lymphoblastic anemia.
    Hunger SP
    Hematology Am Soc Hematol Educ Program; 2011; 2011():361-5. PubMed ID: 22160058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 10-year complete remission in a Philadelphia chromosome-positive acute lymphoblastic leukemia patient using imatinib without high-intensity chemotherapy or allogeneic stem cell transplantation.
    Fujimaki K; Hattori Y; Nakajima H
    Int J Hematol; 2018 Jun; 107(6):709-711. PubMed ID: 29188580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tyrosine kinase inhibitor therapy or transplant in children with Philadelphia chromosome-positive acute lymphoblastic leukaemia: striking the balance.
    Ottmann O
    Lancet Haematol; 2018 Dec; 5(12):e606-e607. PubMed ID: 30501865
    [No Abstract]   [Full Text] [Related]  

  • 6. Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia.
    Brissot E; Labopin M; Beckers MM; Socié G; Rambaldi A; Volin L; Finke J; Lenhoff S; Kröger N; Ossenkoppele GJ; Craddock CF; Yakoub-Agha I; Gürman G; Russell NH; Aljurf M; Potter MN; Nagler A; Ottmann O; Cornelissen JJ; Esteve J; Mohty M
    Haematologica; 2015 Mar; 100(3):392-9. PubMed ID: 25527562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation between deletion of the CDKN2 gene and tyrosine kinase inhibitor resistance in adult Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Xu N; Li YL; Li X; Zhou X; Cao R; Li H; Li L; Lu ZY; Huang JX; Fan ZP; Huang F; Zhou HS; Zhang S; Liu Z; Zhu HQ; Liu QF; Liu XL
    J Hematol Oncol; 2016 Apr; 9():40. PubMed ID: 27090891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic factors and outcomes of unrelated bone marrow transplantation for Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) pre-treated with tyrosine kinase inhibitors.
    Yoshimura T; Nakane T; Hirose A; Koh H; Nakamae M; Aimoto M; Nishimoto M; Hayashi Y; Terada Y; Nakamae H; Hino M
    Osaka City Med J; 2013 Jun; 59(1):9-21. PubMed ID: 23909077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
    Ottmann OG; Pfeifer H
    Hematology Am Soc Hematol Educ Program; 2009; ():371-81. PubMed ID: 20008223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Daver N; Thomas D; Ravandi F; Cortes J; Garris R; Jabbour E; Garcia-Manero G; Borthakur G; Kadia T; Rytting M; Konopleva M; Kantarjian H; O'Brien S
    Haematologica; 2015 May; 100(5):653-61. PubMed ID: 25682595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Imatinib in combination with allogeneic hematopoietic stem cell transplantation improved the outcome of adult Philadelphia chromosome-positive acute lymphoblastic leukemia].
    Cheng Z; Zhao L; Chen G; Wu D; Qiu H; Tang X; Fu C; Jin Z; Chen F; Xue S; Sun A
    Zhonghua Xue Ye Xue Za Zhi; 2014 Feb; 35(2):114-9. PubMed ID: 24606651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Second-generation tyrosine kinase inhibitors combined with allogeneic hematopoietic stem cell transplant for Philadelphia chromosome positive leukemia].
    Yu X; Li C; Wu X; Ye L; Liu H; Ma C; Ma J; Gu C; Wu D
    Zhonghua Xue Ye Xue Za Zhi; 2014 Feb; 35(2):129-33. PubMed ID: 24606654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spontaneous subdural hematoma in a patient with Philadelphia chromosome-positive acute lymphoblastic leukemia with normal platelet count after dasatinib treatment.
    Mustafa Ali MK; Sabha MM; Al-Rabi KH
    Platelets; 2015; 26(5):491-4. PubMed ID: 25025538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improvement of Bone Marrow Necrosis by Tyrosine Kinase Inhibitor Substitution in a Pediatric Patient With Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia.
    Mikami T; Kato I; Oiki N; Okamoto S; Kamitori T; Tasaka K; Ogata H; Tanaka K; Umeda K; Hiramatsu H; Okamoto T; Adachi S; Takita J
    J Pediatr Hematol Oncol; 2022 Mar; 44(2):e539-e542. PubMed ID: 33843813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Successful induction and long-term molecular remission with imatinib mesylate and chemotherapy in a case of Ph-positive acute lymphoblastic leukemia].
    Hirayama Y; Sakamaki S; Takayanagi N; Tsuji Y; Sagawa T; Chiba H; Maeda M; Matsunaga T; Kato J; Niitsu Y
    Rinsho Ketsueki; 2003 May; 44(5):334-8. PubMed ID: 12822409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dasatinib monotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia with pulmonary infection in induction remission: A case report and review of the literature.
    Zhang C; Luo XQ; Zhang X
    Medicine (Baltimore); 2018 Sep; 97(38):e12308. PubMed ID: 30235679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Philadelphia chromosome-positive mixed phenotype acute leukemia in the imatinib era.
    Shimizu H; Yokohama A; Hatsumi N; Takada S; Handa H; Sakura T; Nojima Y
    Eur J Haematol; 2014 Oct; 93(4):297-301. PubMed ID: 24750307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tyrosine Kinase Inhibitor for Treatment of Adult Allogeneic Hematopoietic Stem Cell Transplantation Candidate with Philadelphia-Positive Acute Lymphoblastic Leukemia.
    Wang L; Liu DH
    Chin Med J (Engl); 2017 Jan; 130(2):127-129. PubMed ID: 28091401
    [No Abstract]   [Full Text] [Related]  

  • 19. Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Ravandi F; O'Brien SM; Cortes JE; Thomas DM; Garris R; Faderl S; Burger JA; Rytting ME; Ferrajoli A; Wierda WG; Verstovsek S; Champlin R; Kebriaei P; McCue DA; Huang X; Jabbour E; Garcia-Manero G; Estrov Z; Kantarjian HM
    Cancer; 2015 Dec; 121(23):4158-64. PubMed ID: 26308885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful second allogeneic stem cell transplantation in second remission induced by dasatinib in a child with Philadelphia chromosome positive acute lymphoblastic leukemia.
    Millot F; Cividin M; Brizard F; Chomel JC; Méchinaud F; Guilhot F
    Pediatr Blood Cancer; 2009 Jul; 52(7):891-2. PubMed ID: 19202569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.